Skip to main content

Advertisement

Table 2 Characteristics of cases and controls during the year after A/H1N1 2009 pandemic influenza

From: Lessons from a French collaborative case–control study in cystic fibrosis patients during the 2009 A/H1N1 influenza pandemy

  n Cases (n = 44) n Controls (n = 371) p
Change in FEV1, %, mean (SD)     
 Month 1 12 8.3 (19.2) 198 −2.3 (8.4) 0.08
 Month 3 17 0.6 (7.8) 211 −2.5 (8.7) 0.14
 Month 12 28 1.2 (13.3) 249 −1.8 (11.0) 0.67
Change in FVC, %, mean (SD)     
 Month 1 12 7.4 (18.1) 198 −3.9 (8.8) 0.05
 Month 3 17 0.7 (8.7) 212 −2.5 (8.9) 0.16
 Month 12 28 1.9 (12.7) 252 −2.6 (9.8) 0.10
Antibiotics, number of treatments, mean (SD)    
 Oral 44 2.8 (2.4) 371 1.8 (2.1) 0.002
 Intravenous 44 0.6 (1.3) 371 0.8 (1.54) 0.42
New bronchopulmonary colonization, n (%)    
 Any germ 44 13 (30) 371 151 (41) 0.60
H. influenza 44 1 (2) 371 32 (8) 0.13
S. aureus 44 3 (7) 371 39 (11) 0.42
P. aeruginosa 44 6 (14) 371 36 (10) 0.48
B. cepacia 44 0 371 5 (1) 0.42
A. fumigatus 44 3 (7) 371 39 (11) 0.42
Oxygen therapy, n (%) 44 2 (5) 371 30 (8) 0.41
Noninvasive ventilation, n (%) 44 2 (5) 371 12 (3) 0.65
  1. Both are compared to reference data and expressed as percent predicted values, based on age, gender, and height
  2. FEV1 forced expiratory volume in one second, FVC forced vital capacity, SD standard deviation